BioSpace News Archive

10x Genomics, Inc., a leader in single cell and spatial biology, announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data for researchers worldwide.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) has received 510(K) clearance from the U.S. Food and Drug Administration for its innovative Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of Herpes simplex virus type 1 (HSV-1).

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.

Immunovant, Inc. (Nasdaq: IMVT) today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical trial of batoclimab in patients with Graves’ disease meaningfully exceeded 50% response rates.

Immunis, Inc., a private biotechnology company developing innovative secretome therapeutics for age and disease-related immune dysfunction, is honored to win two 2023 Best of America Small Business Awards.

BioCity Biopharma today announced dosing of the first patient in a Phase Ib/II clinical trial of its anti-TIM-3 monoclonal antibody (mAb) BC3402 in combination with IMFINZI (durvalumab) for the treatment of advanced hepatocellular carcinoma (HCC) in China.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”)'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon® delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

Glaukos Corporation today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia , Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.

Radiant Biotherapeutics, a startup biotechnology company developing a revolutionary antibody platform to deliver transformative therapies for patients facing life-changing disease, announced it has received a USD $2 million grant from the Bill & Melinda Gates Foundation to develop the next generation of HIV biologics based on Radiant’s Multabody™ platform.